Linezolid versus vancomycin for methicillin-resistant staphylococcus aureus nosocomial pneumonia: Controversy continues

Clinical Infectious Diseases

Volumn 55, Issue 1, 2012, Pages 161-

  Masuta, Kana ^a   Oba, Yuichiro ^a   Iwata, Kentaro ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); HOSPITAL INFECTION; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL;

EID: 84862207926     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis331     Document Type: Letter

References (4)

1. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis [Internet] 2011 Jan 4 [cited 2012 Feb 14]; Available from: http://cid.oxfordjournals.org/content/early/2011/01/04/cid.ciq146.full.
3. Que YA, Moreillon P. Staphylococcus aureus (including Staphylococcus toxic shock). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier, 2010:2543-78.
4. Howden BP. Linezolid. In: Grayson ML, et al., eds. Kucers' the use of antibiotics. 6th ed. London: Hodder Arnold, 2010:895-919.